Supplemental Fig. S3. Forest plot highlighting the side effect profile of the use of gemigliptin as compared to controls focusing on (A) symptomatic hypoglycaemia, (B) asymptomatic hypoglycaemia, (C) post-prandial blood glucose (at 24 weeks), (D) mean average glucose excursion. M-H, Mantel-Haenszel; CI, confidence interval; SD, standard deviation; IV, inverse variance.